IDRAPARINUX (SANORG 34006) FOR TREATMENT AND SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMOLIC EVENTS IN PATIENTS WITH DEEP VENOUS THROMBOSIS

摘要

The invention relates to a dose of 2.5 mg of the pentasaccharide methyl O-(2,3,4-tri-O-methyl-6-O-sulfo--D-glucopyranosyl)-(14)-O-(2,3-di-O-methyl--D-glucopyranosyl uronic acid)-(14)-O-(2,3,6-tri-O-sulfo--D-glucopyranosyl)-(14)-O-(2,3-di-O-methyl--L-idopyranosyl uronic acid)-(14)-2,3,6-tri-O-sulfo--D-glucopyranoside or a pharmaceutically acceptable salt thereof for use in therapy, in particular for the treatment of venous thromboembolic events in patients with deep venous thrombosis.